Editor's key points † The authors reviewed the evidence for the use of pregabalin for pain relief in the perioperative period. † They found a significant positive effect (in terms of improved pain scores, opioid-sparing and reduction in nausea, vomiting, and pruritus), but a slight increase in some side-effects.
. 2 Studies investigating the perioperative use of pregabalin used doses ranging from 50 to 300 mg and daily doses ranging from 50 to 750 mg. The efficacy of perioperative administration of pregabalin was investigated in previous meta-analyses, 3 -5 with all showing better postoperative analgesia with pregabalin. Those metaanalyses grouped studies based on the total daily dose of pregabalin. Zhang and colleagues 5 reported that pregabalin doses of ,300 and ≥300 mg day 21 reduced 24 h opioid consumption but not pain scores after surgery. Engelman and Cateloy 4 grouped the analysis over a wide time-frame (6 h-7 days after surgery) according to the daily dose of pregabalin 225 -300, and 600-750 mg) and reported that the lowest effective dose for reducing postoperative analgesic consumption was 225-300 mg with no reduction in pain scores. Since doses were reported in those meta-analyses as total daily dose, it is not clear if the individual dose or frequency of administration of pregabalin affect outcome. For instance, it is not clear from those reviews if individual single doses lower than 225-300 mg have analgesic efficacy or if twice daily dosing of a particular dose of pregabalin would be more effective than single preoperative administration of the same dose. Some studies have investigated the impact of pregabalin on preoperative anxiety, but this was not addressed in those previous meta-analyses. More than 30 studies investigating perioperative pregabalin administration on acute pain outcomes have been published after the publication of those reviews, which included 11 5 and 18 4 studies. In addition, while one previous meta-analysis 3 assessed the impact of the perioperative administration of pregabalin on chronic pain, it included only three studies. 6 -8 Seven other studies 9 -15 addressing persistent pain after pregabalin administration have since been published. Therefore, we performed this systematic review to provide an updated meta-analysis of the impact of pregabalin EDITOR'S CHOICE administration on postoperative pain scores and opioid consumption and investigate whether those outcomes differ according to individual pregabalin dose, frequency of administration, type of anaesthesia, or type of surgery. Secondary aims were to assess the impact of pregabalin administration on anxiety scores and persistent pain, and provide an updated meta-analysis of the side-effects of pregabalin administration.
Methods
We followed the recommendations of the PRISMA statement.
tramide. 20 If ketorolac was the only analgesic used, it was converted to ME using a conversion factor of 3:1. 21 If results were not reported at the time points specified in this analysis, those recorded close to those time points were used instead.
To evaluate different pregabalin dosing regimens, we performed subgroup analyses for pain scores and opioid consumption at 2 h after operation according to the individual dose of pregabalin administered before surgery (≤75, 100-150, and 300 mg). For pain scores and opioid consumption at 24 h, we performed a subgroup analysis according to the dose and frequency of administration of pregabalin comparing the three dose levels (≤75, 100-150, and 300 mg) and single vs multiple dosing at each dose level. Single dosing refers to studies that administered a single preoperative dose of pregabalin, while multiple dosing refers to studies that used at least one postoperative dose of pregabalin in addition to the preoperative dose or administered more than one preoperative dose. We also performed sensitivity analyses according to the type of surgery and type of anaesthesia (general vs regional) for the primary outcomes of pain scores and opioid consumption at 2 and 24 h. To evaluate predictors that could impact our primary outcomes, we also performed a meta-regression using pregabalin dose, type of surgery, and type of anaesthesia (general or regional) as predictors for the 2 h outcomes. The frequency of administration of pregabalin (single vs multiple dosing) was used as an additional predictor for 24 h outcomes.
Preoperative anxiety
We pooled preoperative anxiety scores after administration of pregabalin compared with placebo. VAS scores for anxiety reported as 0-100 were converted to the 0-10 scale for analysis.
Side-effects of perioperative pregabalin administration
We pooled adverse effects after administration of pregabalin compared with placebo. If an event rate was reported over multiple time intervals instead of the entire duration of the study, the highest recorded incidence over the duration of the study was used in the analysis. Sedation was defined as scores 3-6 on the Ramsay sedation scale (1, patient is anxious and agitated or restless; 2, patient is co-operative, oriented, and tranquil; 3, patient responds to commands only; 4, patient exhibits brisk response to light glabellar tap or loud auditory stimulus; 5, patient exhibits a sluggish response to light glabellar tap or loud auditory stimulus; 6, patient exhibits no response), 2-5 on the five-point scale (1, completely awake; 2, awake but drowsy; 3, asleep but responsive to verbal commands; 4, asleep but responsive to tactile stimulus; 5, asleep and not responsive to any stimulus), and 2-4 on the four-point scale (1, awake; 2, mild sedation; 3, sleepy but rousable; and 4, very sleepy), while severe sedation was considered for scores 4-6, 4-5, and 3-4 on the Ramsay, five-point scale, and four-point scale, respectively. In studies investigating sedation on the four-point scale (none, mild, moderate, and severe), sedation was defined as any sedation (mild, moderate, or severe). If sedation was not reported, somnolence or drowsiness was used instead for the analysis.
Persistent pain
We compared the incidence of persistent pain at 1, 3, 6, and 12 months after surgery after pregabalin vs placebo administration. We also compared pain scores at 1 and 3 months after surgery between pregabalin and placebo.
Continuous data were summarized as mean difference (MD) with 95% confidence interval (CI). If the 95% CI included a value of 0, we considered that the difference between pregabalin and placebo was not statistically significant. Dichotomous data were summarized as relative risk (RR) with 95% CI. If the 95% CI included a value of 1, we considered the difference not statistically significant. If the pooled results were not statistically significant and the CIs included values that exceeded a 30% difference in the pregabalin group compared with the control group, we considered that no conclusion could be derived from the pooled results due to the wide CIs. Analyses were performed using the Review Manager (RevMan), Version 5.1, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011, and Comprehensive Meta-Analysis Software (version 3.0). A random effects model (which assumes that the effects being estimated in the different studies are not identical, but follow some distribution) was used. 17 We assessed heterogeneity using the I 2 -test. Heterogeneity was assumed to be present if the I 2 was .50%. Forest plots were used to graphically represent and evaluate treatment effects. Subgroup analysis was performed using the Q-test. We assessed for publication bias for the primary outcomes using the Egger's test. 22 We also performed a sensitivity analysis for the primary outcomes after removing papers with an unclear or high risk of bias. To exclude a small study effect, we compared the results of the random effects and fixed effect models for our primary outcomes. We assessed the proportion of the total variance explained by each of the covariates (R 2 ) included in the meta-regression (pregabalin dose, frequency of administration, type of anaesthesia, and type of surgery) for the primary outcomes. Meta-regression was performed using the method of moments.
Results
Six hundred and ninety-five studies were assessed for inclusion in this review (Fig. 1 pain. 6 -15 The characteristics of the included studies are shown in Table 1 . The risk of bias of the included studies is shown in Table 2 .
Primary outcomes

Pain scores
Pain scores at 2 h Pain scores at rest at 2 h (Fig. 2) For pain scores at rest, 9% of the total variance was explained by the dose of pregabalin used, 11% by the type of surgery, and 1% by the type of anaesthesia. For pain scores on movement, 16% of the total variance was explained by the dose of pregabalin, 10% by type of surgery, and none was explained by type of anaesthesia. In subgroup analysis, pain scores at rest were reduced with all doses of pregabalin (Fig. 2 ). Pain scores with movement were only reduced with the 300 mg dose. There were no significant differences between the three dose groups for pain at rest (P¼0.95) or with movement (P¼0.29). Sensitivity analysis according to type of surgery showed a reduction in pain scores at rest for all types of surgery except minor surgery and cardiac surgery (Table 3) . Pain scores on movement were only reduced in open abdominal and head and neck surgeries. Pain scores at rest and on movement were reduced in studies using general anaesthesia but not regional anaesthesia.
The meta-regression found type of surgery (P¼0.02), but not pregabalin dose (P¼0.74) or type of anaesthesia (0.16) to be a significant predictor of 2 h pain scores at rest. The type of anaesthesia was a significant predictor of pain scores on movement at 2 h (P¼0.046), but not type of surgery (P¼0.10) or pregabalin dose (0.81).
Pain scores at 24 h Pain scores at rest at 24 h (Fig. 3) at rest and on movement, respectively). For pain scores at rest, 1% of the total variance was explained by the dose of pregabalin used, 32% by the type of surgery, 0.28% by the frequency of pregabalin administration, and none was explained by the type of anaesthesia. For pain scores on movement, type of surgery explained 26% of the total variance and type of anaesthesia 0.22%. The dose of pregabalin and frequency of administration did not explain any of the total variance. In subgroup analysis, pain scores at rest were reduced with pregabalin doses ≥100 mg, but not ≤75 mg (Fig. 3) , with no significant differences between dose levels (P¼0.87). When accounting for dosing frequency (Table 4) , pain scores at rest were not reduced by any of the doses of pregabalin compared with placebo when given in single doses, but were reduced with multiple dosing of pregabalin ≤75 mg (P¼0.03) and 100-150 mg (P¼0.0001). There were no significant differences between single and multiple dosing at the ≤75 mg (P¼0.17), 100 -150 mg (P¼0.86), or 300 mg (P¼0.27) dose levels. Pain scores at rest were only reduced in open abdominal and head and neck surgeries (Table 3) . Sensitivity analysis according to type of anaesthesia showed a reduction in pain scores at rest with general but not regional anaesthesia. The meta-regression found type of surgery (P¼0.008), but not type of anaesthesia (P¼0.21), pregabalin dose (P¼0.67), or pregabalin frequency (P¼0.61) to be a significant predictor of 24 h pain scores at rest.
Pain scores on movement were reduced only with doses of 300 mg compared with placebo, but there were no significant differences between the three dose levels of pregabalin (P¼0.42). When accounting for dosing frequency ( In subgroup analysis, opioid consumption was reduced by the 100 -150 and 300 mg doses compared with placebo, but not the ≤75 mg dose (Fig. 4) . This reduction was significantly different among the three groups (P¼0.005) with pairwise comparisons showing significantly lower opioid sparing in the ≤75 mg group compared with the 100 -150 mg (P¼0.001) and the 300 mg (P¼0.0007) groups, and no difference between the 100-150 and 300 mg groups. Sensitivity analysis according to type of surgery showed a reduction in opioid consumption at 2 h in orthopaedic, open abdominal, and minor surgical procedures. Two hours opioid sparing was seen with general anaesthesia but not regional anaesthesia (Table 3 ). In the meta-regression model, pregabalin dose was a significant predictor of 2 h opioid consumption (P¼0.02), but not type of surgery (P¼0.34) or type of anaesthesia (0.34).
Opioid consumption at 24 h Opioid consumption at 24 h (Fig. 5) was investigated in 29 studies. 8 In subgroup analysis, all doses of pregabalin reduced 24 h opioid consumption compared with placebo when given as a single preoperative dose or as multiple doses (Table 3 ). There were no statistically significant differences between administration of a single preoperative dose and administration of multiple doses for the ≤75 mg (P¼0.87), 100-150 mg (P¼0.44), and the 300 mg (P¼0.66) dose levels. There were also no significant differences between the three dose levels of pregabalin when all studies were combined (P¼0.25, Fig. 5) . Opioid consumption at 24 h was reduced in all types of surgery except minor surgical procedures and head and neck surgery. Pooled results of both general anaesthesia and regional anaesthesia studies showed a reduction in 24 h opioid consumption ( Table 3) .
The type of anaesthesia was a significant predictor of 24 h opioid consumption (P¼0.0496) in the meta-regression model, but not type of surgery (P¼0.11), pregabalin dose (P¼0.92), or frequency of pregabalin administration (P¼0.26).
Sensitivity analysis according to study risk of bias assessment Our sensitivity analysis showed no difference in primary outcomes when papers with unclear risk of bias Comparing random effects and fixed effect models for primary outcomes The fixed effect model yielded very comparable results with the random effects model for the primary outcomes of our review.
Secondary outcomes
Duration of PACU and hospital stay
The duration of PACU stay was reported in four studies 28 34 46 49 and duration of hospital stay or time to achieve hospital discharge criteria in five studies. 6 Tau Tau months at rest were investigated in three studies 7 9 13 and during movement in two studies 7 9 with no statistically significant differences between the groups. The incidence of persistent pain at 1, 3, 6, and 12 months were reported in four, 8 11 -13 six, 6 8 11 13 -15 two, 6 12 and two 12 14 studies, respectively. Two studies specified that the pain was neuropathic, 6 12 while the other five studies 8 10 11 13 14 reported the presence of persistent pain without specifying the type. Both studies specifying that the pain was neuropathic reported a significant reduction in the incidence of neuropathic pain with pregabalin at 3, 6 6, . Excluding studies with a higher baseline risk of persistent pain 13 14 did not change the overall results. For the 3 month assessment, excluding the one study reporting neuropathic pain 6 abolished the heterogeneity but did not change the overall pooled results [RR (95% CI)¼0.88 (0.60, 1.30,
Excluding one study with a high risk of bias 12 leaves only one study for the 6 and 12 month assessments. For the 6 month assessment, the study by Buvanendran and colleagues 6 reported a statistically significant reduction in the incidence of neuropathic pain with pregabalin (P¼0.014), while at 12 months, the study by Gianesello and colleagues 14 did not report a reduction in the incidence of pain in pregabalintreated patients.
Side-effects
Side-effects are presented in Table 5 . Sedation, severe sedation, and dizziness at 24 h, and visual disturbance up to 24 h were significantly more common in pregabalin-treated patients. At 0-2 h, no conclusion could be reached about those outcomes due to the wide CIs of the pooled results. On the other hand, the administration of pregabalin was associated with a lower incidence of postoperative nausea and vomiting (PONV) and pruritus at 24 h when compared with control. Sedation scores at 2 and 24 h were reported using a VAS scale in seven 8 
11 23 36 46 20.67 
8 13 37 38 43 50 51 54 57 210.02 (214.91, 25.14), 
Severe sedation NA 0.50 (0.03, 7.41), 
39 -42 7 .79 (1.02, 59.37), 28 67 Pregabalin and postoperative pain sedation according to pregabalin dosing regimens is presented in Table 3 . There was a statistically significant increase in the risk of sedation with single and multiple dosing of pregabalin 300 mg and the risk of severe sedation with multiple doses of 300 mg. The CIs with other pregabalin regimens were wide, suggesting that the data are insufficient to draw conclusions with the lower two doses of pregabalin.
Preoperative anxiety scores
Preoperative anxiety scores after pregabalin administration were investigated in 10 studies (general anaesthesia in nine 
Discussion
In this systematic review and meta-analysis, we found that the perioperative administration of pregabalin was associated Tau with a statistically significant reduction in pain scores at rest (MD of 0.81 at 2 h and 0.38 at 24 h), pain scores during movement (MD of 0.58 at 2 h, and 0.47 at 24 h), and opioid consumption (MD of 2.09 mg ME at 2 h, and 8.27 mg ME at 24 h) after surgery compared with placebo. The incidence of opioidrelated side-effects (PONV and pruritus) was significantly reduced with pregabalin administration by 38% and 51%, respectively, relative to placebo at 24 h after surgery. The administration of pregabalin was associated with a significantly higher incidence of sedation (46% increase), dizziness (33% increase), and visual disturbance (3.5 times more likely) relative to placebo. Of note, pregabalin-treated patients achieved hospital discharge criteria 14 h earlier than controls. Although we were not able to reach a definitive conclusion regarding preoperative anxiety due to the wide CIs of the non-statistically significant pooled results, six of the 10 studies investigating preoperative anxiety reported significantly lower anxiety with pregabalin. Similarly for persistent pain, we were not able to reach a conclusion regarding the incidence at 3 months, while at 6 and 12 months, there was limited information suggesting a possible benefit. The only two studies investigating neuropathic pain reported a benefit from pregabalin administration. The optimal dose or frequency of administration of pregabalin is unclear. 69 In the included studies, the individual dose of pregabalin administered before surgery ranged from 50 to 300 mg. Our analyses suggested that the opioid-sparing effect of pregabalin seemed to be limited to doses 100 -150 and 300 mg but not ≤75 mg at 2 h after surgery, whereas at 24 h, no statistically significant differences were detected between the three dose levels. These doses are lower than the lowest effective daily dose of 225 mg suggested in an earlier meta-analysis. 4 Pregabalin has an elimination half-life estimated to range from 5.5 to 6.7 h which is independent of the dose and frequency of administration. 69 With nearly half the included trials studying single dosing while the other half using multiple dosing, we investigated whether the frequency of administration impacts the analgesic efficacy of pregabalin. While the opioid-sparing effect was statistically significant with both single and multiple dosing of pregabalin ≤75-300 mg, the reduction in pain scores seemed to be limited in general to multiple dosing. The further reduction in pain scores with multiple dosing over single dosing however was modest and likely not clinically relevant. In fact, there were no statistically significant differences between single and multiple dosing with regard to opioid consumption and pain scores, except for pain scores on movement with the ≤75 mg dose. These results might suggest that for acute pain outcomes, there is no significant benefit of repeated dosing of pregabalin compared with a single preoperative dose. This agrees with the results of the only study that prospectively compared single dose of pregabalin 150 mg vs three perioperative doses and reported no difference in acute pain outcomes between the groups. 26 In a previous meta-analysis, Clarke and colleagues 3 investigated the incidence of persistent pain at 3-6 months after surgery and, pooling results from two studies, reported an odds ratio (95% CI) of 0.09 (0.02-0.52) with pregabalin compared with control. More recently, Chaparro and colleagues 70 investigated the incidence of persistent pain at 3 months after surgery and found a reduction in this incidence with pregabalin after pooling the results of four studies [RR (95% CI)¼0.70 (0.51, 0.95)]. However, the authors stated that these positive results in favour of pregabalin were mainly due to one positive study, while the other three studies showed no benefit. This positive overall result is likely due to the use of the fixed effect model in that review. We however used a random effects model, which we deemed more appropriate, given the clinical heterogeneity of the studies, and including six studies, we found the data insufficient to reach a conclusion about pain at 3 months due to the wide CIs of the pooled results. While we found a statistically significant reduction in the incidence of persistent pain at 6 months [RR (95% CI)¼0.31 (0.10, 0.92) and 12 months [0.47 (0.23, 0.97)], each of these two analyses included only two studies, with one of them 12 having a high risk of bias. Only two studies investigated neuropathic pain, 6 12 with both studies reporting a benefit from pregabalin administration; however, one of those studies 12 had a high risk of bias. The optimum pregabalin regimen needed for affecting chronic pain is not clear. Most of the studies studying the impact of pregabalin on chronic pain used multiple doses starting before operation and extending to several days after operation. 6 -8 10 12-15 Studies comparing the impact of single vs multiple dosing of pregabalin on the incidence of chronic post-surgical pain are lacking. Overall, pregabalin produced a clinically relevant opioid sparing of 25% at 24 h. The impact on pain scores was less pronounced with 19% and 16% reduction in the mean pain scores at rest and on movement at 24 h, and therefore might not be clinically relevant. Pregabalin-induced opioid sparing was however associated with a reduction in opioid-related side-effects such as PONV and pruritus. However, these benefits were at the expense of increased risk of sedation and dizziness. The available 44 66 data allowed only limited assessment of the impact of sedation on patients' recovery. For instance, only four studies reported on the duration of PACU stay, and this did not seem to be impacted by pregabalin. Furthermore, interestingly, the duration of hospital stay was reduced with pregabalin administration, but this was only reported in five of the included studies. Since type of surgery and type of anaesthesia can influence postoperative analgesic outcomes, we included both in addition to pregabalin dosing in the meta-regression models. In fact, both were significant predictors of some of the outcomes in our analysis. For instance, type of surgery was a significant predictor of pain scores at rest at 2 and 24 h. This agrees with previous studies showing that type of surgery is a significant predictor of postoperative analgesic outcomes. 71 The type of anaesthesia also predicted 2 h pain scores on movement and 24 h opioid consumption, likely due to the analgesic effect of regional anaesthesia in the early postoperative period. There are several limitations to this review: -Heterogeneity: We combined different types of surgery, different pregabalin doses, different anaesthetic types, and different regimens (single and multiple dosing) in our main analysis, which created heterogeneity within that analysis. It has been suggested that this is expected and inevitable in a meta-analysis, and that any amount of heterogeneity is acceptable, provided that the predefined eligibility criteria for the meta-analysis are sound and the data are correct. 72 In order to investigate the efficacy of different dosing regimens of pregabalin and the efficacy of pregabalin in different types of surgery and with different anaesthetic techniques, we performed a number of sensitivity and subgroup analyses and meta-regressions. However, results from these analyses should be regarded as observational in nature, may be biased and limited by the small number of studies included in some of the subgroups, and should therefore be interpreted with caution. 17 While included trials might have allocated treatment randomly, their inclusion in this review is not random. Furthermore, while we used a random effects meta-analysis due to the clinical heterogeneity, this method weighs the studies more equally than a fixed effect meta-analysis. To exclude a small study effect on the results of our analysis, we compared the results of the fixed and random effects model on our primary outcomes and those yielded comparable results further strengthening the internal validity of our findings.
-Risk of bias in individual studies: Limiting the review to RCTs limits the potential for bias. Our risk of bias assessment indicated that most included studies had a low risk of bias. Furthermore, our sensitivity analysis excluding the few studies with unclear or high risk of bias did not affect our conclusions. Another limitation was the inconsistency of reporting outcomes among the studies, and the lack of response from some authors with regard to data that we requested. However, the results of our review were consistent in the various sensitivity analyses. Some important clinically relevant outcomes such as the duration of PACU stay and of hospital stay were only rarely reported.
Multiple areas for future research have been identified. Large studies with adequate power are needed to compare the efficacy and side-effect profile of different doses of pregabalin. Studies are also needed to assess the efficacy and side-effects of single vs multiple dosing of pregabalin. In addition, further investigation is needed to assess the ideal pregabalin regimen for the reduction in persistent pain in surgical patients. Those studies should focus on surgeries associated with a high risk of chronic post-surgical pain. Studies also need to specifically address neuropathic pain and make a distinction between different types of persistent pain.
In conclusion, this systematic review and meta-analysis confirms previous meta-analyses suggesting that the perioperative administration of pregabalin is associated with a significant reduction in opioid consumption after surgery. In this review, we also found a significant reduction in pain scores with pregabalin administration. The impact on opioid consumption seemed to be more pronounced, while the reduction in pain scores was only modest. Other new findings from our review are the fact that the analgesic effect of pregabalin seemed to be associated with much lower doses than previously reported. 4 Furthermore, our review suggested that overall there was no difference in acute pain outcomes between single and multiple dosing of pregabalin. Neuropathic pain might be reduced with pregabalin, but available data are sparse. Consistent with previous meta-analyses, sedation, dizziness, and visual disturbance occurred more commonly in pregabalin-treated patients.
